RT @drhungo: @fergonleon STRONG-HF 👉🏼 https://t.co/6hjlV8i0rS CHAMP-HF 👉🏼 https://t.co/psEG6aWICc
RT @GHF_Acad: #Heartfailure patients with reduced ejection fraction often miss out on crucial medications. This study, the CHAMP-HF registr…
RT @GHF_Acad: #Heartfailure patients with reduced ejection fraction often miss out on crucial medications. This study, the CHAMP-HF registr…
#Heartfailure patients with reduced ejection fraction often miss out on crucial medications. This study, the CHAMP-HF registry, underscores the importance of targeted improvements in care. Review Findings: https://t.co/Bx910g8Uhq Source: ScienceDirect
RT @drhungo: Clinical inertia at its best 🐌 Every appointment is an opportunity to refine a patients care 🔎 Stage A-B 🫀failure 👉🏼 aggres…
RT @DmitryAbramovMD: A national campaign is needed to encourage patients with HF to ask their treatment team why they are not on 4 classes…
RT @drhungo: Clinical inertia at its best 🐌 Every appointment is an opportunity to refine a patients care 🔎 Stage A-B 🫀failure 👉🏼 aggres…
RT @drhungo: Clinical inertia at its best 🐌 Every appointment is an opportunity to refine a patients care 🔎 Stage A-B 🫀failure 👉🏼 aggres…
Clinical inertia at its best 🐌 Every appointment is an opportunity to refine a patients care 🔎 Stage A-B 🫀failure 👉🏼 aggressively 🎯 risk factors Stage C-D 🫀failure 👉🏼 review, add, uptitrate EARLY ‼️ #CardioTwitter #MedTwitter #MedEd #FOAMed
RT @DmitryAbramovMD: A national campaign is needed to encourage patients with HF to ask their treatment team why they are not on 4 classes…
A national campaign is needed to encourage patients with HF to ask their treatment team why they are not on 4 classes of GDMT at every encounter.
@paomorejon Justo acabo de escribir esto mismo en otro hilo. Tenemos telepatía!
@gcfmd @JonathanDavisHF @AndrewJSauer @hvanspall @ShelleyZieroth @Jcontreras75 @JJheart_doc @AnastasiaSMihai @RyanTedfordMD @DrNasrien @dranulala I am very worried about the lack of improvement of MRA prescription over time 2018: Champion-HF Registry, MRA
@fergonleon STRONG-HF 👉🏼 https://t.co/6hjlV8i0rS CHAMP-HF 👉🏼 https://t.co/psEG6aWICc
RT @RyanTedfordMD: @KashviGupta @JRWinterfield @gcfmd @JJheart_doc Both? One of many National examples: https://t.co/PeRzkdRXr5 We’ve try…
@drjohnm @JavedButler1 @djc795 @gcfmd @kaulcsmc @hvanspall @PLooserMD @mvaduganathan @DLBHATTMD @nancy_m_albert @SJGreene_md @NMHheartdoc @boback @AndrewFoy82 @DavidLBrownMD @RichardLehman1 I saw a patient in clinic last week who was on quadruple therapy f
RT @RyanTedfordMD: @KashviGupta @JRWinterfield @gcfmd @JJheart_doc Both? One of many National examples: https://t.co/PeRzkdRXr5 We’ve try…
@KashviGupta @JRWinterfield @gcfmd @JJheart_doc Both? One of many National examples: https://t.co/PeRzkdRXr5 We’ve trying to tackle this @MUSChealth and with new inpatient HF pathways and our HF discharge clinic.
Another disappointing HFrEF statistic. In CHAMP-HF registry <25% of patients received any doses of all 3 doses of GDMT (BB, ARNI, ARA). Likely even worse now that we have a 4th agent (SGLT2i) https://t.co/BKYFOY6FPF
@bjdickmayhew Challenges in GDMT prescribing in Heart Failure patients (despite the highest recommendation from medical societies and is concordant with clinician's knowledge) should inform how we think of influencing clinician behavior. https://t.co/nkkcm
Yesterday was the good HFrEF news, here is the bad news: <1% of patients were treated with max tolerated doses of all GDMT meds in the CHAMP-HF registry. And this is before SGLT2I’s we’re added to GDMT! https://t.co/BKYFOY6FPF
@SanjayGill1 These are all true, and I find them hard to use also, but 1/3 is all they’re comfortable with? https://t.co/ew55nzotjX
4/ 🎯 What about target doses? CHAMP-HF showed we collectively do a poor job of optimizing GDMT. 👇🏾 https://t.co/cVqWpwXroP In their supplement, we find "Target Doses of Guideline-Directed Medical Therapies" by clinical practice guidelines https://t.co/
I love this - take the failure out of heart failure!! Titrate those GDMTs 💕
RT @NUIM_Chiefs: #Pearl 5: It is imperative to treat HFrEF patients with the proper medications at optimal dosages. In the CHAMP-HF registr…
#Pearl 5: It is imperative to treat HFrEF patients with the proper medications at optimal dosages. In the CHAMP-HF registry 1% of pts were treated with target does of all appropriate classes of GDMT. Time to take the 'failure' out of 'heart failure' https:
@FudimMarat @_adevore @texhern @JacobMD11 @ericpetersonMD @gcfmd @NMHheartdoc @robmentz @DCRINews @AHA_Research @SJGreene_md @GianluSava @ValleAlfonso @pmyhre @ACCinTouch Surprisingly, the prescription rate of MRA in HFrEF is also low; despite strong evide
RT @SophiaAirhart: Love this thread, let’s get more docs to walk the walk 👣 & prescribe evidence based medical therapy Results of the CHA…
Love this thread, let’s get more docs to walk the walk 👣 & prescribe evidence based medical therapy Results of the CHAMP-HF data sobering: @JavedButler1 @_adevore @gcfmd @jspertus @texhern @JACCJournals https://t.co/hTFDMcIGCH 👣@NMHheartdoc summar
RT @gcfmd: Thanks @hvanspall. Two more below. Targeted performance improvement interventions have been shown to reduce site variation and…
Thanks @hvanspall. Two more below. Targeted performance improvement interventions have been shown to reduce site variation and improve use of GDMT. More focused efforts to improve dosing are needed. https://t.co/ypt6P0iWCh https://t.co/obHiSkX7Sk
RT @SJGreene_md: In current US outpatient practice, there remain major gaps in use & dosing of proven #HFrEF medications. An important oppo…
RT @HannaGaggin: Another great #MedicineArticles that I missed but resurfaced on twitter. Sobering. Only 1% of HFrEF patients (CHAMP-HF Reg…
Another great #MedicineArticles that I missed but resurfaced on twitter. Sobering. Only 1% of HFrEF patients (CHAMP-HF Registry) getting #GDMT doses of ACEI/ARB, BB and MRA, associated with older age, low BP/NYHA, CKD, recent HF hospitalization.
RT @saratabtabai: We have found the same in our local population and are working on novel ways to address and improve achieving GDMT in our…
@vikasaggarwalmd @umichCVC @LindenfeldJoann @GreggWStone Agree - lots of work to do in this regard! https://t.co/UWZNY8bElL
Opportunities for improvement in patient care and outcomes in those with heart failure https://t.co/0xJpjDO4Dg https://t.co/gTsnQqnbMX
RT @kdfaulkenberg: Striking underutilization and underdosing of evidence-based medication in #HFrEF but #pharmacist-driven medication prog…
Striking underutilization and underdosing of evidence-based medication in #HFrEF but #pharmacist-driven medication programs can help close the gap https://t.co/NGkQiG2fLV https://t.co/TjBAUHLJnK
RT @KevinShahMD: 8️⃣ Misc: ➖ SGLT2 inhibitors in patients with HF and DM (EMPA-REG & CANVAS) ➖ Optimization of HF therapies that work are…
RT @KevinShahMD: 8️⃣ Misc: ➖ SGLT2 inhibitors in patients with HF and DM (EMPA-REG & CANVAS) ➖ Optimization of HF therapies that work are…
RT @KevinShahMD: 8️⃣ Misc: ➖ SGLT2 inhibitors in patients with HF and DM (EMPA-REG & CANVAS) ➖ Optimization of HF therapies that work are…
8️⃣ Misc: ➖ SGLT2 inhibitors in patients with HF and DM (EMPA-REG & CANVAS) ➖ Optimization of HF therapies that work are underutilized (CHAMP-HF: https://t.co/JJVW3g7630) ➖ Improved insight in mechanism will improve therapies for HFpEF TreatHF app: h
RT @SJGreene_md: In current US outpatient practice, there remain major gaps in use & dosing of proven #HFrEF medications. An important oppo…
RT @JACCJournals: Are we missing the boat when it comes to using guideline HFrEF meds? https://t.co/9rbFCylt6Q #JACC @UCLAHealth @gcfmd @…
RT @javierchimeno: ¿Están bien tratados nuestros pacientes con ICC con FE reducida? 🤔 Pues parece que la mayoría no... 😰😰 https://t.co/Jczo…
RT @javierchimeno: ¿Están bien tratados nuestros pacientes con ICC con FE reducida? 🤔 Pues parece que la mayoría no... 😰😰 https://t.co/Jczo…
RT @javierchimeno: ¿Están bien tratados nuestros pacientes con ICC con FE reducida? 🤔 Pues parece que la mayoría no... 😰😰 https://t.co/Jczo…
RT @javierchimeno: ¿Están bien tratados nuestros pacientes con ICC con FE reducida? 🤔 Pues parece que la mayoría no... 😰😰 https://t.co/Jczo…
RT @javierchimeno: ¿Están bien tratados nuestros pacientes con ICC con FE reducida? 🤔 Pues parece que la mayoría no... 😰😰 https://t.co/Jczo…
RT @javierchimeno: ¿Están bien tratados nuestros pacientes con ICC con FE reducida? 🤔 Pues parece que la mayoría no... 😰😰 https://t.co/Jczo…
¿Están bien tratados nuestros pacientes con ICC con FE reducida? 🤔 Pues parece que la mayoría no... 😰😰 https://t.co/JczoXT6LPi #inerciaterapeutica #malaadherencia ... https://t.co/0dc8LQ1iH5
Medical Therapy for Heart Failure With Reduced Ejection Fraction https://t.co/aBVMRApGdC
RT @paomorejon: 🚨A pesar de la evidencia, sólo 1% tiene dosis objetivo🚨 #InsuficienciaCardiaca •Una década del IMPROVE-HF, poco ha cambiad…
RT @JACCJournals: What has prevented you from getting to target doses of guideline-directed medical therapy in HFrEF? https://t.co/6LsXKguh…
RT @JACCJournals: What has prevented you from getting to target doses of guideline-directed medical therapy in HFrEF? https://t.co/6LsXKguh…
RT @JACCJournals: What has prevented you from getting to target doses of guideline-directed medical therapy in HFrEF? https://t.co/6LsXKguh…
RT @paomorejon: 🚨A pesar de la evidencia, sólo 1% tiene dosis objetivo🚨 #InsuficienciaCardiaca •Una década del IMPROVE-HF, poco ha cambiad…
RT @JACCJournals: What has prevented you from getting to target doses of guideline-directed medical therapy in HFrEF? https://t.co/6LsXKguh…
RT @krychtiukmd: This heart failure registry data in @JACCJournals is more than alarming - patients are undertreated or even untreated! Wh…
RT @JACCJournals: What has prevented you from getting to target doses of guideline-directed medical therapy in HFrEF? https://t.co/6LsXKguh…
RT @krychtiukmd: This heart failure registry data in @JACCJournals is more than alarming - patients are undertreated or even untreated! Wh…
RT @krychtiukmd: This heart failure registry data in @JACCJournals is more than alarming - patients are undertreated or even untreated! Wh…
RT @JACCJournals: What has prevented you from getting to target doses of guideline-directed medical therapy in HFrEF? https://t.co/6LsXKguh…
RT @paomorejon: 🚨A pesar de la evidencia, sólo 1% tiene dosis objetivo🚨 #InsuficienciaCardiaca •Una década del IMPROVE-HF, poco ha cambiad…
RT @JACCJournals: What has prevented you from getting to target doses of guideline-directed medical therapy in HFrEF? https://t.co/6LsXKguh…
RT @krychtiukmd: This heart failure registry data in @JACCJournals is more than alarming - patients are undertreated or even untreated! Wh…
RT @JACCJournals: What has prevented you from getting to target doses of guideline-directed medical therapy in HFrEF? https://t.co/6LsXKguh…
RT @krychtiukmd: This heart failure registry data in @JACCJournals is more than alarming - patients are undertreated or even untreated! Wh…
RT @krychtiukmd: This heart failure registry data in @JACCJournals is more than alarming - patients are undertreated or even untreated! Wh…
RT @paomorejon: 🚨A pesar de la evidencia, sólo 1% tiene dosis objetivo🚨 #InsuficienciaCardiaca •Una década del IMPROVE-HF, poco ha cambiad…
RT @paomorejon: 🚨A pesar de la evidencia, sólo 1% tiene dosis objetivo🚨 #InsuficienciaCardiaca •Una década del IMPROVE-HF, poco ha cambiad…
RT @paomorejon: 🚨A pesar de la evidencia, sólo 1% tiene dosis objetivo🚨 #InsuficienciaCardiaca •Una década del IMPROVE-HF, poco ha cambiad…
RT @JACCJournals: What has prevented you from getting to target doses of guideline-directed medical therapy in HFrEF? https://t.co/6LsXKguh…
What has prevented you from getting to target doses of guideline-directed medical therapy in HFrEF? https://t.co/6LsXKguhRU #JACC
RT @krychtiukmd: This heart failure registry data in @JACCJournals is more than alarming - patients are undertreated or even untreated! Wh…
RT @krychtiukmd: This heart failure registry data in @JACCJournals is more than alarming - patients are undertreated or even untreated! Wh…
RT @krychtiukmd: This heart failure registry data in @JACCJournals is more than alarming - patients are undertreated or even untreated! Wh…
This heart failure registry data in @JACCJournals is more than alarming - patients are undertreated or even untreated! What are the solutions? @MihaiTrofenciuc @JGrapsa @GiuseppeGalati_ @editgara @rafavidalperez @HillLoreena @Filippatos #heartfailure ht
RT @JACCJournals: Are we missing the boat when it comes to using guideline HFrEF meds? https://t.co/9rbFCylt6Q #JACC @UCLAHealth @gcfmd @…
RT @paomorejon: 🚨A pesar de la evidencia, sólo 1% tiene dosis objetivo🚨 #InsuficienciaCardiaca •Una década del IMPROVE-HF, poco ha cambiad…
RT @paomorejon: 🚨A pesar de la evidencia, sólo 1% tiene dosis objetivo🚨 #InsuficienciaCardiaca •Una década del IMPROVE-HF, poco ha cambiad…
RT @paomorejon: 🚨A pesar de la evidencia, sólo 1% tiene dosis objetivo🚨 #InsuficienciaCardiaca •Una década del IMPROVE-HF, poco ha cambiad…
RT @paomorejon: 🚨A pesar de la evidencia, sólo 1% tiene dosis objetivo🚨 #InsuficienciaCardiaca •Una década del IMPROVE-HF, poco ha cambiad…
RT @gcfmd: Vital opportunity to improve use and dosing of GDMT for HFrEF. Medical Therapy for Heart Failure With Reduced Ejection Fraction…
RT @paomorejon: 🚨A pesar de la evidencia, sólo 1% tiene dosis objetivo🚨 #InsuficienciaCardiaca •Una década del IMPROVE-HF, poco ha cambiad…
RT @SJGreene_md: In current US outpatient practice, there remain major gaps in use & dosing of proven #HFrEF medications. An important oppo…
RT @paomorejon: 🚨A pesar de la evidencia, sólo 1% tiene dosis objetivo🚨 #InsuficienciaCardiaca •Una década del IMPROVE-HF, poco ha cambiad…